Literature DB >> 8951374

HIV-1 reverse transcriptase discriminates against non-self tRNA primers.

B B Oude Essink1, A T Das, B Berkhout.   

Abstract

The interactions between the Reverse Transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) and the natural tRNA(Lys3) primer for initiation of viral DNA synthesis were examined. We constructed a set of HIV-1 RNA templates in which the wild-type primer binding site (PBS(Lys3)) is replaced by sequences complementary to tRNA(lle), tRNA(Lys1,2), tRNA(Phe), tRNA(Pro) or tRNA(Trp) and tested the ability of RT enzymes of different retroviral species to initiate cDNA synthesis from self versus non-self tRNA primers. We demonstrate that initiation of HIV-1 reverse transcription is a specific process that is most efficient with the self tRNA(Lys3) primer. Interestingly, the property of HIV-1 RT to discriminate against non-self tRNA primers is lost upon extension of the tRNA by only two deoxyribonucleotides. Furthermore, selective tRNA priming by HIV-1 RT was not observed with viral RNA-tRNA(Lys3) duplexes isolated from HIV-1 virion particles, suggesting that the majority of tRNA(Lys3) primers annealed to viral RNA in particles is extended by a variable number of deoxyribonucleotides. This result indicates that reverse transcription is initiated relatively early in nascently assembled virions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951374     DOI: 10.1006/jmbi.1996.0638

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  21 in total

1.  Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription.

Authors:  N Beerens; F Groot; B Berkhout
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus.

Authors:  B Berkhout; M Jebbink; J Zsíros
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

3.  Mutational analysis of the tRNA3Lys/HIV-1 RNA (primer/template) complex.

Authors:  C Isel; G Keith; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  1998-03-01       Impact factor: 16.971

4.  Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  N K Back; B Berkhout
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Switching the in vitro tRNA usage of HIV-1 by simultaneous adaptation of the PBS and PAS.

Authors:  Nancy Beerens; Ben Berkhout
Journal:  RNA       Date:  2002-03       Impact factor: 4.942

6.  Assembly, purification and crystallization of an active HIV-1 reverse transcriptase initiation complex.

Authors:  Janice D Pata; Bradford R King; Thomas A Steitz
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

7.  RNase H requirements for the second strand transfer reaction of human immunodeficiency virus type 1 reverse transcription.

Authors:  C M Smith; J S Smith; M J Roth
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  On the importance of the primer activation signal for initiation of tRNA(lys3)-primed reverse transcription of the HIV-1 RNA genome.

Authors:  Hendrik Huthoff; Katarzyna Bugala; Jan Barciszewski; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

9.  Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions.

Authors:  C K Damgaard; H Dyhr-Mikkelsen; J Kjems
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

10.  Role of the primer activation signal in tRNA annealing onto the HIV-1 genome studied by single-molecule FRET microscopy.

Authors:  Nancy Beerens; Mette D E Jepsen; Volodymyr Nechyporuk-Zloy; Asger C Krüger; Jean-Luc Darlix; Jørgen Kjems; Victoria Birkedal
Journal:  RNA       Date:  2013-02-12       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.